A
Alcista
Alcista · 25%ALKS
$29.09
Precio del escenario
$39.080
-0.641 (-1.64%)Al cierre
Loading chart…
- Máximo
- 40.650
- Apertura
- 39.590
- Precio medio ponderado por volumen
- 39.57
- Volumen
- 1.55M
- Capitalización
- 4.11B
- Mínimo
- 38.980
- Importe
- 61.38M
- EV/EBITDA, TTM
- 21.30
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Análisis de IA of Alkermes Plc (ALKS)
MantenerAlkermes Plc is currently a hold. The stock is priced at $40.61, with a forward P/E ratio of 133.33, indicating high valuation expectations. Although the company has shown strong revenue growth of 27.5% year-over-year, recent insider selling and a low RSI of 38.997 suggest caution. The main risk is the significant drop in net income, which was -66.48 million USD in Q1 2026, indicating potential volatility ahead.
Recomendaciones de analistas (12)
+18.22% de potencial alcista
Mantener
5 Comprar
7 Mantener
0 Vender
Actual: 39.08
Mínimo
37.00
Promedio
46.20
Máximo
58.00
Baird
Superar al mercado
$61
2026-09-22
Baird
2026-09-22
Precio objetivo
$61
Superar al mercado
H.C. Wainwright
Neutral
—
2026-09-21
H.C. Wainwright
2026-09-21
Precio objetivo
—
Neutral
Mizuho
Superar al mercado
$65
2026-09-04
Mizuho
2026-09-04
Precio objetivo
$65
Superar al mercado
JPMorgan
Neutral
$61
2026-07-29
JPMorgan
2026-07-29
Precio objetivo
$61
Neutral
Baird
Superar al mercado
$58
2026-07-29
Baird
2026-07-29
Precio objetivo
$58
Superar al mercado
Métricas de valoración
El PER previsto actual de Alkermes Plc (ALKS) es 133.33, frente a su media de 5 años de 93.05.
Escenarios de precio de Alphio AI para ALKS
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con ALKS en cartera
Cronología de eventos
Noticias
9.009-21NewsfilterALKS 7290 Shows Clinically Meaningful Improvements in Adult ADHD Symptoms
5.008-29NASDAQ.COMAlkermes Executive Sells 7,576 Shares, Reducing Holdings
5.008-29FoolAlkermes Executive Sells 7,576 Shares Amid Strong Performance
- 9.008-24Newsfilter
Alixorexton Shows Significant Improvements in Narcolepsy Treatment
- 9.507-28seekingalpha
Alkermes Q2 2026 Earnings Call Insights
Preguntas frecuentes sobre ALKS, respondidas por Alphio AI
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Alkermes Plc is currently a hold. The stock is priced at $40.61, with a forward P/E ratio of 133.33, indicating high valuation expectations. Although the company has shown strong revenue growth of 27.5% year-over-year, recent insider selling and a low RSI of 38.997 suggest caution. The main risk is the significant drop in net income, which was -66.48 million USD in Q1 2026, indicating potential volatility ahead.
12 analysts cover ALKS: 5 rate it Buy, 7 Hold and 0 Sell. The average price target is 46.20.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.